SCID Bu/Flu/ATG Study With T Cell Depletion

Severe Combined Immunodeficiency Clinical Trial

Official title:

Phase I/II Trial of Hematopoietic Stem Cell Transplant (HSCT) for Children With Severe Combined Immune Deficiency (SCID) and Without an HLA-Matched Sibling Donor

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02127892
• Other study ID #: CCI-06-00243
• Status: Terminated
• Phase: Phase 1/Phase 2
• First received: October 19, 2012
• Last updated: August 18, 2017
• Start date: January 2, 2007
• Est. completion date: August 1, 2016

Study information

• Verified date: August 2017
• Source: Children's Hospital Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with a diagnosis of Severe Combined Immune Deficiency (SCID) who do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD), 2) unrelated cord blood donor, or 3) a haplo-identical (parental) donor (in descending order of preference).Patients will receive a novel conditioning regimen with Busulfan, Fludarabine and Anti-thymocyte globulin (ATG) followed by an unrelated donor hematopoietic stem cell transplant (HSCT) with T-cell depletion using the CliniMACS device.

Description:

The study is being conducted to assess the following:

• overall survival

• event-free survival (events are defined as: death,non-engraftment/2nd transplant, immune reconstitution failure)

• acute toxicity of the conditioning regimen

• engraftment frequency immune reconstitution frequency and tempo acute and chronic graft-versus-host disease (GVHD), frequency and severity.

The outcome from this protocol will be compared to the retrospective cohort consisting of all patients who have undergone haplo-identical HSCT for SCID at CHLA from 1984-2006 based on the assessment of the above-listed endpoints.

The CliniMACS device will be used for CD34+ selection in place of the Isolex 300i. The CliniMACS CD34 Reagent System is an investigational medical device that has not yet been approved by the FDA. This device is used in vitro to select and enrich specific cell populations. When using the CliniMACS CD34 Reagent, the system selects CD34+ cells from heterogenous hematological cell populations for transplantation in cases where this is clinically indicated.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: August 1, 2016
• Est. primary completion date: August 1, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• All patients with SCID who lack a histocompatible sibling or HLA-matched related donor will be considered as candidates for this study protocol.

• Eligible patients must have adequate physical function to tolerate the chemotherapy conditioning regimen and the HSCT, as measure by:

1. Renal: creatinine clearance or GFR =50 ml/min/1.73m2, and not requiring dialysis

2. Pulmonary: Because patients with SCID frequently present with infectious pneumonia causing ventilatory failure, patients will be considered for enrollment in the study even if respiratory failure requiring mechanical ventilatory support is present. In patients recently diagnosed with pneumonia, efforts to stabilize the respiratory status will be made prior to enrollment in the study.

3. Infectious disease status. The presence of infection per se will not be a reason for exclusion from the study. Patients with SCID are frequently infected with both routine pathogens as well as opportunistic infections. Antibiotic, antifungal and antiviral prophylaxis and therapy will be instituted as clinically indicated. Despite the use of antimicrobial therapy, the ability to control infections will not be achieved unless HSCT is performed. Therefore, subjects may be enrolled in the study, even though infection is present, because control of infection may depend on engraftment of a donor immune system.

4. Patients will be 0-21 years of age.

Exclusion Criteria:

• Patient with histocompatible sibling or other related donor

• End-organ failure that precludes the ability to tolerate the transplant procedure, including conditioning.

• Renal failure requiring dialysis

• Congenital heart disease resulting in congestive heart failure

• Severe CNS disease, e.g., coma or intractable seizures

• Ventilatory failure due to non-infectious etiology

• Major congenital anomalies that adversely affect survival, eg CNS malformations

• Metabolic diseases that would affect transplant survival, eg urea cycle disorders

• HIV infection

Since the only chance of survival for patients with SCID is successful transplantation, all patients with SCID will be considered to be potential subjects for the study, regardless of end-organ dysfunction.

Related Conditions & MeSH terms

• Immunologic Deficiency Syndromes
• Severe Combined Immunodeficiency

Intervention

Biological:
• unrelated BM with T cell depletion
Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
• unrelated cord blood
Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
• haplo BM with T cell depletion
haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.

Device:
• unrelated PBSC with T cell depletion
peripheral blood stem cell will be processed for CD34+ cell isolation.

Locations

Country	Name	City	State
United States	Children's Hospital Los Angeles	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
Neena Kapoor, M.D.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of Participants With Veno-occlusive Disease (VOD) - Moderate and Severe	Evaluation of veno-occlusive disease determined by the presence of the following features; fluid retention, weight gain, leaky capillary syndrome, painful liver enlargement, refractoriness to platelet tranfusion and hyperbilirubinemia	100 days
Other	Number of Participants With Graft Versus Host Disease (GVHD) - Grade III or IV	GVHD disease surveillance done by clinical evaluation, to include history, physical examination, specifically for rash, jaundice, liver dysfunction, nausea and vomiting, diarrhea and failure to thrive.	1 year
Other	Overall Survival	Overalls survival of patient at 1 year post transplant	1 year
Primary	Number of Participants With Engraftment	Engraftment is defined as recovery of blood counts (neutrophil and platelet engraftment) with cells of donor origin, documented by either bone marrow or peripheral blood chimerism assays after hematopoietic stem cell transplant.	100 day
Secondary	Number of Participants With Donor-derived CD3+ T Lymphocytes >/= 100/mm3	Absolute number of donor-derived CD3+ T lymphocytes >/= 100/mm3 in participating subjects.	1 year